Current Hepatitis Reports

, Volume 6, Issue 3, pp 91–95 | Cite as

Management of hepatitis B in patients with HBeAg-negative disease

  • Walid S. Ayoub
  • Emmet B. KeeffeEmail author


Chronic hepatitis B with negative hepatitis B e antigen (HBeAg) is becoming a more prevalent form of chronic hepatitis B. This change is the result of selection pressure on the virus leading to a precore or double core promoter mutation of hepatitis B virus that either abolishes or downregulates synthesis of HBeAg. De novo acute infection with HBeAg-negative mutant virus rarely leads to chronic infection but usually results in acute hepatitis with a course ranging from benign to fulminant. Chronic HBeAg-negative hepatitis B is thought to evolve from wildtype HBeAg-positive chronic hepatitis B and is associated with a worse natural history than HBeAg-positive disease. Long-term treatment is required to maintain suppression of viral replication when using the oral nucleoside or nucleotide analogues, which have improved management of this condition. However, the need for extended therapy makes strategies to reduce or avoid resistance to antiviral drugs an important consideration.


Lamivudine Adefovir Entecavir Emtricitabine Adefovir Dipivoxil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen negative chronic hepatitis B. Hepatology 2001, 34:617–624.PubMedCrossRefGoogle Scholar
  2. 2.
    Yim HJ, Lok ASF: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006, 43:S173–S181.PubMedCrossRefGoogle Scholar
  3. 3.
    Fattovich G: Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47–58.PubMedCrossRefGoogle Scholar
  4. 4.
    Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001, 120:1828–1853.PubMedCrossRefGoogle Scholar
  5. 5.
    Keeffe EB, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936–962.PubMedCrossRefGoogle Scholar
  6. 6.
    Hadziyannis SJ, Papatheodoridis GV: Hepatitis B e antigen negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006, 26:130–141.PubMedCrossRefGoogle Scholar
  7. 7.
    Hadziyannis SJ: Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Reviews 1995, 1:7–36.Google Scholar
  8. 8.
    Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B virus infection. Hepatology 2002, 35:1522–1527.PubMedCrossRefGoogle Scholar
  9. 9.
    Chu CJ, Keeffe EB, Han SH, et al.: Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003, 38:619–628.PubMedCrossRefGoogle Scholar
  10. 10.
    Papatheodoridis GV, Dimou E, Dimakopoulos K, et al.: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005, 42:121–129.PubMedCrossRefGoogle Scholar
  11. 11.
    Papatheodoridis GV, Hadziyannis SJ: Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001, 8:311–321.PubMedCrossRefGoogle Scholar
  12. 12.
    Chu CJ, Hussain M, Lok AS: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002, 36:1408–1415.PubMedGoogle Scholar
  13. 13.
    Manesis EK, Hadziyannis SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001, 121:101–109.PubMedCrossRefGoogle Scholar
  14. 14.
    Marcellin P, Lau GK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206–1217.PubMedCrossRefGoogle Scholar
  15. 15.
    Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999, 29:889–896.PubMedCrossRefGoogle Scholar
  16. 16.
    Santantonio T, Mazzola M, Iacovazzi T, et al.: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000, 32:300–306.PubMedCrossRefGoogle Scholar
  17. 17.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of HBeAg-negative chronic hepatitis B. N Engl J Med 2003, 348:800–807.PubMedCrossRefGoogle Scholar
  18. 18.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B. N Engl J Med 2005, 352:2673–2681.PubMedCrossRefGoogle Scholar
  19. 19.
    Hadziyannis S, Tassopoulos N, Chang TT, et al.: Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B (results after 5 years of therapy) [abstract]. Hepatology 2005, 42(suppl 1):754A.Google Scholar
  20. 20.
    Yang H, Qi X, Das K, et al.: In vitro characterization and molecular modeling analysis of novel adefovir resistance mutation RTN236T in the HBV polymerase [abstract]. J Hepatol 2004, 40(suppl 2):114.CrossRefGoogle Scholar
  21. 21.
    Aloman C, Wands JR: Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy. Hepatology 2003, 38:1584–1587.PubMedCrossRefGoogle Scholar
  22. 22.
    Seifer M, Hamatake RK, Colonno RJ, et al.: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998, 42:3200–3208.PubMedGoogle Scholar
  23. 23.
    Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011–1026.PubMedCrossRefGoogle Scholar
  24. 24.
    Shouval D, Akarca U, Hatzis G, et al.: Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg-chronic hepatitis B patients (study ETV-027) [abstract]. J Hepatol 2006, 130(suppl 2):S21–S22.CrossRefGoogle Scholar
  25. 25.
    Yurdaydin C, Sollano J, Hadziyannis S, et al.: Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg+ chronic hepatitis B patients (ETV-026) [abstract]. J Hepatol 2006, 130(suppl 2):S36.CrossRefGoogle Scholar
  26. 26.
    Colonno RJ, Rose RE, Pokornowski K, et al.: Four years assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients [abstract]. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver; April 11–15, 2007; Barcelona, Spain. Abstract 781.Google Scholar
  27. 27.
    Tenney DJ, Levine SM, Rose RE, et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004, 48:3498–3507.PubMedCrossRefGoogle Scholar
  28. 28.
    Lai C, Gane E, Hsu C, et al.: Two-year results from GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine [abstract]. Hepatology 2006, 44(suppl 1):222A.Google Scholar
  29. 29.
    Benhamou Y, Fleury H, Trimoulet P, et al.: Anti-hepatitis B virus efficacy of tenofivir disoproxil fumarate in HIV-infected patients. Hepatology 2006, 43:548–555.PubMedCrossRefGoogle Scholar
  30. 30.
    van Bommel F, Wunsche T, Mauss S, et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infection. Hepatology 2004, 40:1421–1425.PubMedCrossRefGoogle Scholar
  31. 31.
    Dore GJ, Cooper DA, Pozniak AL, et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004, 189:1185–1192.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhu Y, Delaney W, Curtis M, et al.: Anti-HBV activity of in vitro combinations of tenofovir with nucleoside analogs [abstract]. Hepatology 2006, 44(suppl 1):253A.Google Scholar
  33. 33.
    Gish R, Leung N, Wang C, et al.: Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given one daily emtricitabine for 2 years [abstract]. Hepatology 2003, 38(suppl 1):372A.Google Scholar
  34. 34.
    Shiffman ML, Ng TM, Krastev Z, et al.: A double-blind, placebo controlled trial of emtricitabine (FTC, Emtriva) administered once daily for the treatment of chronic hepatitis B virus (HBV) infection [abstract]. Hepatology 2004, 40(suppl 1):172A (Abstract 22).Google Scholar
  35. 35.
    Lok ASF, McMahon BJ: AASLD practice guidelines: chronic hepatitis B. Hepatology 2007, 45:507–539.PubMedCrossRefGoogle Scholar
  36. 36.
    Hadziyannis SJ, Seveastianos V, Rapti IN, et al.: Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B [abstract]. Hepatology 2006, 44(suppl 1):231A.Google Scholar

Copyright information

© Current Medicine Group, LLC 2007

Authors and Affiliations

  1. 1.Palo AltoUSA

Personalised recommendations